A ROS-responsive hydrogel delivering LOXL2-loaded nanoparticles reduced senescence, oxidative stress, and matrix breakdown in experimental disc degeneration.
Evidence
This preclinical platform study combined nucleus pulposus cell mechanism work with an injectable LNP-LOXL2@Gel intervention in a rat model.
Caveat
The therapeutic claim rests on cell and rat model data with partial functional restoration, not human clinical testing.
Simplified
BACKGROUND: (IDD) is a chronic degenerative disorder marked by nucleus pulposus cells (NPCs) senescence and extracellular matrix (ECM) degradation, which is a key pathological factor leading to low back pain. Current clinical treatments are mainly limited to symptomatic relief without effectively reversing the degenerative process.
RESULTS: We revealed that lysyl oxidase-like protein 2 (LOXL2) is involved in the molecular mechanism of NPCs senescence through the regulation of the Notch signaling pathway, and developed a novel therapeutic strategy. We propose an injectable, degradable and ROS-responsive hydrogel delivery system (LNP-LOXL2@Gel), which mimics the biomechanical properties of natural intervertebral disc tissues and can be used as a sustained-release vehicle for LNP-LOXL2. Its ROS scavenging ability complements the intracellular anti-aging effect of LOXL2, blocking the cascade of "oxidative stress--ECM degradation". In the rat IDD model, LNP-LOXL2@Gel not only reduced nucleus pulposus senescence, but also inhibited ECM catabolism by decreasing the expression of ROS in the microenvironment, thus partially restoring the physiological function of the intervertebral disc.
CONCLUSIONS: LOXL2 expression is down-regulated in degenerated discs, and its overexpression inhibits the Notch pathway and delays NPCs senescence. The LNP-LOXL2@Gel hydrogel system, which can effectively alleviate IDD by synergistically integrating the antiaging effect of LOXL2 and the ROS scavenging ability of PVA-tsPBA, provides a new targeting therapeutic strategy for the clinical treatment of IDD.
Key numbers
DHI
Decrease in DHI
Disc Height Index (DHI) assessed at 4/8 weeks postoperatively.
1.5-2.2×
1.5-2.2× increase
Notch signaling mRNA expression levels in after treatment.
Full Text
We can’t show the full text here under this license.
